INTRODUCTION
Although Shigella dysenteriae serotype 1 (Shiga) toxin was discovered more than 80 years ago (18) and has long been recognized as one of the most potent bacterial toxins (18, 116) , early efforts to characterize its structure, biologic activity, genetics, role in pathogenesis, and other properties were hindered by difficulties in preparing pure toxin, obtaining appropriate immunologic reagents, and conducting genetic studies with S. dysenteriae 1. The enterotoxicity of Shiga toxin was first reported in 1972 (59) . Other important advances that have been made during the past decade include the following: (i) purification of Shiga toxin to homogeneity (7, 21, 81, 87, 120) ; (ii) identification of cell surface receptors for toxin (8, 45 press); (iii) demonstration that the intracellular action of toxin causes an inhibition of protein synthesis (7, 8a, 97, 111; T. G. Obrig, T. P. Moran, and J. E. Brown, J. Biol. Chem., in press); (iv) recognition SHIGA TOXIN IN SHIGELLA SPP. History Shigellosis, the severest form of which was historically called bacillary dysentery, is a disease limited to humans and certain other primates (24) . The bacteria that cause shigellosis belong to the genus Shigella and are classified into four species and over 40 serotypes on the basis of the characteristics of their 0 antigens. The species of Shigella are S. dysenteriae (serogroup A), S. flexneri (serogroup B), S. boydii (serogroup C), and S. sonnei (serogroup D).
Shigella spp. colonize the large bowel and must penetrate and multiply within colonic epithelial cells to cause disease in volunteers (25, 70) . The pathophysiology of shigellosis is beyond the scope of this review and is discussed in detail elsewhere (57, 58) . Typical symptoms of shigellosis include cramps, painful defecation, fever, diarrhea, dysentery (blood and mucus in stools), or diarrhea and dysentery (24) . All four species of Shigella have been shown to contain large plasmids (120 to 140 megadaltons) that are required for the organism to invade epithelial cells (101) (102) (103) (104) . At least three chromosomally encoded determinants must also be expressed for shigellae to be fully virulent in animal models (102) , but the specific gene products made by them have not been established.
Shigella spp. also elaborate a toxin, designated as Shiga toxin, that may contribute to the development of necrotic lesions of the colon. Several detailed reviews on Shiga toxin have been published over the last 50 years (12, 30, 57, 58, 113, 116) . The Shiga toxin was first described in 1903 by Conradi, who reported that intravenous inoculation of autolysates of Shiga's bacillus (Shigella dysenteriae 1) paralyzed and killed rabbits (18) . It was subsequently shown that various animal species exhibit differential susceptibilities to the lethal effects of Shiga toxin, but only the rabbit and mouse display neurological symptoms (14) . Studies in the 1950s suggested that Shiga toxin does not act directly on neurons (i.e., is not actually a neurotoxin) but that it can cause secondary neurological disorders by its action on the vascular system of the brain and spinal cord (6, 43) . More recent data concerning the interaction of Shiga toxin with neurons are controversial. Wiley et al. (118) reported that purified Shiga toxin can be axonally transported to rat vagal sensory neurons and can kill those neurons. In contrast, Brown et al. failed to demonstrate axonal transport of purified Shiga toxin, nor were they able to show cytotoxicity or specific binding of toxin to neuroblastoma hybrid cells (J. E. Brown Although the paralytic-lethal effects of crude Shiga toxin were originally demonstrated in the early part of this century, it was not until the 1940s that such preparations were reported to be cytotoxic for selected mammalian cells (69, 115) . Subsequently, Keusch et al. (59) showed that partially purified preparations of Shiga toxin could elicit fluid accumulation, i.e., were enterotoxic, in ligated segments of rabbit ileum. When purified Shiga toxin became available in the 1980s, several groups independently demonstrated that the paralytic-lethal, cytotoxic, and enterotoxic activities described for extracts or culture filtrates of Shiga's bacillus could be ascribed to a single toxin (7, 21, 28, 81) . These varied biological properties appear to reflect the molecular action of Shiga toxin, i.e., inhibition of protein synthesis in susceptible target cells (9, 10, 97, 111) , as discussed in a subsequent section of this review.
Purification and Structure
The following two points relevant to all purification schemes should be emphasized: (i) Shiga toxin is a cellassociated toxin that may be located in the periplasmic space (20, 37) and released into the culture medium after cell death (23, 114) ; and (ii) the yield of Shiga toxin is increased if the bacteria are cultured in a medium with a reduced iron content or a medium that has been adjusted to a high pH (23, 79, 114) . Purification of the Shiga toxin to homogeneity was first reported in 1980 (81, 87) , and several new and modified purification procedures have subsequently been published (7, 21, 80, 88, 120) . The protocol for toxin purification now used in our laboratory (80) is representative of the various schemes. The shigellae are grown in an iron-depleted, modified glucose syncase broth (79, 82) . The organisms are harvested by centrifugation and lysed in a French pressure cell, and the lysates are then clarified by ultracentrifugation and passed over an Affi-Gel Blue (Bio-Rad Laboratories, Richmond, Calif.) column. Toxin which binds to the Affi-Gel Blue is eluted from the column and subsequently purified by chromatofocusing and antitoxin affinity chromatography. About 60% of the cytotoxin activity present in the starting cell lysates is recovered, but the amount of purified protein is low ( (21) , 3 x 108 CD50,/mg (7) , 5 x 108 to 1 x 109 CD50/mg (79, 80) , and 1 x 109 ID50/mg (88) . These differences in specific activity could reflect differences in sensitivity of the HeLa cell sublines used to detect cytotoxin, variations among laboratories in the method used to measure cytotoxicity, or differences in the purity or extent of denaturation of the various toxin preparations.
Past estimates of the molecular weight (MW) of purified Shiga holotoxin have ranged from 58,000 to 70,000 (7, 21, 80, 88) . The 70,000 value appears to be correct as calculated from recent data on subunit MW and subunit stoichiometry. The newest fidings indicated that Shiga toxin comprises one A subunit of MW ca. 32,000 (21) and five copies (21) of a B subunit of MW 7, 700 (106) . The mature B subunit consists of 69 amino acids (106) which agree exactly in composition and sequence with the 69 amino acids inferred from the nucleotide sequence (47a) of the gene for the B subunit of E. coli Shiga-like toxin type I (SLT-I). The A subunit must be nicked by a proteolytic enzyme and its disulfide bonds must be reduced for it to form the enzymatically active A1 fragment of MW 27,000 (88) . The subunit structure of purified Shiga toxin is reminiscent of those of cholera toxin and E. coli heat-labile toxin, but no antigenic cross-reactivity is demonstrable between Shiga toxin and those toxins (81).
Nonetheless, Seidah et al. (106) have proposed on the basis of amino acid sequence data that the B subunits of E. coli heat-labile toxin and cholera toxin are distantly related to the B subunit of Shiga toxin.
VOL. 51, 1987 Although some strains of S. flexneri and S. sonnei (61, 85) (26, 56, 75, 89) . Keusch and Jacewicz (62) (35, 87) . Eiklid and Olsnes (27) observed that 125I-labeled Shiga toxin bound to toxin-sensitive cell lines and to some, but not all, toxin-insensitive lines. These findings indicate that the presence of toxin receptor on a eucaryotic cell is necessary but not sufficient for Shiga toxin to kill that cell; toxin must be internalized and must reach its ribosome target. Shiga toxin appears to enter toxin-sensitive HeLa cells by an endocytotic mechanism (29, 46, 89) .
Inhibition of protein synthesis. Several groups of investigators have demonstrated that Shiga toxin inhibits protein synthesis in eucaryotic cells (8a, 9, 10, 86, 97, 111) . Analysis of the mechanism by which Shiga toxin inhibits protein synthesis has been modeled on previous studies of the mode of action of other bacterial toxins. The prototype protein synthesis-inhibiting bacterial toxins are diphtheria toxin and Pseudomonas exotoxin A (75) . These toxins inactivate elongation factor 2 (EF-2) by NAD-dependent adenosine diphosphate (ADP) ribosylation of a modified histidine residue called diphthamide (75) ; inactivation of EF-2 inhibits peptide chain elongation. Although Shiga toxin also inhibits peptide chain elongation (10, 97) is that Shiga toxin structurally modifies 60S ribosomal subunits, which results in reduced affinity of EF-1 (and subsequently EF-2) for the ribosome. Obrig et al., in a separate report (86) , found that Shiga toxin exhibits ribonuclease (RNase) activity with naked 5S or 5.8S ribosomal RNA (rRNA) of 60S ribosomal subunits acting as substrates; 28S rRNA was not tested. In the same report, Obrig et al. presented evidence that two other ribosome-inactivating toxins, ricin and phytolaccin, also exhibit RNase activity specific for 5S or 5.8S rRNA as substrates (86) . However, the three toxins generated distinct patterns of RNA fragments, which suggests different cleavage sites on the RNAs. As discussed by Obrig et al. (86) , one possible explanation for the findings with Shiga toxin is that the toxin preparation contained a contaminating RNase. The argument presented by Obrig et al. (86) against such a possibility was that the heat inactivation profiles for the RNase and protein synthesis-inhibitory activities of Shiga toxin were similar. It should be noted that despite the apparent RNase activity of Shiga toxin against naked rRNA, no changes in any of the three rRNAs present in intact ribosomes after exposure to Shiga toxin have been observed (Obrig et al., in press).
Immunology and Immunochemistry
Evidence that Shiga and Shiga-like toxins are produced in vivo in sufficient quantities to elicit an immune response was first presented by Keusch and Jacewicz (60) . These investigators reported that the sera of patients with shigellosis due to either S. flexneri or S. sonnei contained antibody that could neutralize the cytotoxic effects of Shiga toxin on HeLa cells. In the same study, Shiga toxin-neutralizing antibody responses in patients with previous S. dysenteriae 1 and S. dysenteriae 2 infections were also demonstrated. The antiShiga toxin response in serum for both natural and experimental infections of humans was reported to be restricted to the immunoglobulin M heavy-chain class (64) . The neutralizing antitoxin in hyperimmune rabbit sera has been reported as being restricted to the immunoglobulin M fraction (64) and the immunoglobulin G fraction (81) . The basis for these discrepant results has not been found.
The question of whether secretory immunoglobulin A anti-Shiga toxin antibodies in the gastrointestinal tract will protect against diarrhea or dysentery caused by Shigella spp. has not been resolved. However, it is clear from studies with rhesus monkeys that high levels of circulating antiShiga toxin antibodies will not protect against oral Shigella infection (74). Monkeys that were vaccinated parenterally with Formalin-inactivated Shiga toxin developed levels of antitoxin in serum which protected them against injection with 1,000 50% mouse lethal doses, but they had diarrhea or dysentery as severe as (or more severe than) unimmunized controls did when they were fed S. dysenteriae 1. Two types of antigenic variants could potentially exist among the family of Shiga and Shiga-like toxins: (i) toxins that are not cross-neutralized by a single reference antiserum, and (ii) partially cross-reacting toxins that are crossneutralized but are not antigenically identical. strains of shigellae and found that 86% of the lysates (other than S. dysenteriae 1) could not be neutralized by anti-Shiga toxin. Whether the cytotoxin(s) present in these strains are related to Shiga toxin but are not cross-neutralizable remains to be determined.
Genetics
Little historical information is available on the genetics of Shiga toxin production. The only mutations reported to affect the yield of shiga toxin are chlorate-resistant mutations in S. dysenteriae 1 (34) that reduce the level of cytotoxin produced (64, 79) . The mutations in those strains were not mapped, nor was the mechanism by which they reduced the yield of cytotoxin determined. In fact, the chlorate-resistant mutants were originally (34) classified as nontoxigenic rather than as low-level toxin producers, because the cytotoxicity assay used in the early 1970s was less sensitive than that now available.
The genes for the Shiga toxin of S. dysenteriae 1 (102), who tentatively localized the region on the S. flexneri chromosome for fluid production in rabbits as being near the lysine decarboxylase (LDS)-negative locus and in the rha-mtl region. Timmis et al. (112) offered two quite plausible explanations for these differences in the localization of the toxin genes: the maps of S. dysenteriae 1 and S. flexneri may not be exactly the same, and S. dysenteriae 1 may carry a second copy of sht. The latter possibility is supported by the mention (112) of an unpublished finding that a second determinant for cytotoxin production is carried on an R'-asn plasmid that also carries the LDS-negative locus of Shigella spp. Timmis et al. (112) (12) . There is no direct proof that Shiga and Shiga-like toxins function as important virulence factors, but there are circumstantial data to support that hypothesis. Dysentery in volunteers fed an invasive, low-toxin-producing (64, 79) , chlorate-resistant mutant of S. dysenteriae 1 designated strain 725 was milder than the disease caused by the invasive, highly toxinogenic parent strain M131. The duration and height of the fever and severity of the dysentery were less in volunteers fed strain 725 than in those fed strain M131 (70) . These clinical observations are in keeping with the idea that the higher level of toxin produced by S. dysenteriae 1 than other Shigella spp. correlates with the more severe disease caused by Shiga's bacillus; dysentery occurs more commonly in patients infected with S. dysenteriae 1 than in those infected with any other serotype of Shigella (57) . One explanation for how Shiga toxin promotes dysentery is that toxin present free in the colonic lumen binds to colonic epithelia and ultimately kills those cells by inhibiting protein synthesis. Two lines of evidence support such a theory. First, measurable toxin is found in human fecal specimens from patients with S. dysenteriae 1 infection (19 Diarrhea. The results of gut perfusion studies (100) done with monkeys also provide evidence for a role of Shiga or Shiga-like toxins in causing the watery diarrhea sometimes seen during shigellosis (24) . All S. flexneri-infected animals showed decreased colonic absorption or net colonic secretion. However, animals with diarrhea also showed net secretion in the jejunum, whereas no jejunal secretion was evident in monkeys with dysentery alone. No invasion of jejunal tissues by Shigella spp. was found in any of the animals, although invasion of the colonic epithelium occurred regularly. Subsequently, Kinsey et al. (65) showed that monkeys inoculated intracecally with S. flexneri had dysentery but not diarrhea. Thus, in monkeys, the diarrhea of shigellosis appears to require a secretory response of the small bowel superimposed on the colonic dysfunction. More recent findings with humans (11) suggest that shigella diarrhea results from colonic dysfunction without evidence for an increased small-bowel flow rate. Wherever the intestinal site for the secretion responsible for shigella diarrhea, one may postulate that the secretion is a consequence of toxin produced by the Shigella spp.
If Shiga toxin is responsible for the diarrhea of shigellosis, a key question is how can a protein synthesis-inhibiting toxin elicit fluid secretion in the intestine? Shiga toxin does not appear to act like cholera toxin or E. coli heat-labile toxin. Although Shiga toxin can elevate the cyclic adenosine monophosphate (cAMP) content of rabbit intestinal mucosa (22) , as can cholera toxin and E. coli heat-labile toxin, Shiga-toxin-induced accumulation of cAMP does not occur until long after fluid secretion begins (H. T. Paulk, A. 0. Cardamone, G. S. Gotterer, and T. R. Hendrix, Gastroenterology 72:1164, 1977) . Shiga toxin also does not appear to act like E. coli heat-stable enterotoxin. Unpublished observations from collaborative studies with R. Guerrant indicate that Shiga toxin does not increase the cyclic guanosine monophosphate (cGMP) content of the rabbit ileum. An alternative mechanism by which Shiga toxin could cause net fluid secretion is to block (or inhibit) fluid absorption. Indeed, Keenan et al. (55) recently reported that purified Shiga toxin and purified E. coli Shiga-like toxin selectively destroyed the mature absorptive epithelial cells of the rabbit ileum. One can therefore propose that Shiga toxin binds to mature absorptive epithelial cells through glycolipid receptors, inactivates protein synthesis in the host cells, and ultimately causes the death of those cells. In this model, Letter, 1983) . S. dysenteriae 1-associated HUS tends to be more severe than E. coli-associated HUS.
The signs of HUS after Shiga infection include disseminated intravascular coagulation, renal microangiopathy, and hemolytic anemia (68) . In one study (68) , 50% of the patients with S. dysenteriae 1-associated HUS had endotoxemia as assessed by the Limulus assay. These symptoms presage a poor prognosis. The clinical manifestations of E. coli 0157:H7-associated HUS are the classic triad described by Gasser et al. (33) . Karmali et al. (52) have suggested that the Shiga toxin of S. dysenteriae 1 or the Shiga-like toxin of E. coli 0157:H7 may enter the bloodstream and cause damage to vascular endothelial cells such as those in the kidneys. This is an attractive hypothesis, because the damage to vascular epithelium seen on autopsy of patients who have died of HUS (68) resembles the histopathological damage to small vessels in the central nervous systems of animals inoculated with crude Shiga toxin (6, 14) . An animal model of HUS has not yet been developed, and the limited availability of purified toxin has hindered studies on the effects of purified toxin in animals.
SHIGA-LIKE TOXINS IN E. COLI

History and Nomenclature
Several different toxins that act on the intestinal tract can be produced by E. coli (Table 1 ). E. coli organisms that cause diarrheal disease in humans and animals have been classified into four groups (71) . Enterotoxigenic E. coli (ETEC) adhere to the mucosa of the small bowel and produce a heat-labile toxin or heat-stable toxin or both. Enteroinvasive E. coli (EIEC) do not produce heat-labile or heat-stable toxin, but, like shigellae, they penetrate and multiply within colonic epithelial cells. Enteropathogenic E. coli (EPEC) were originally incriminated epidemiologically as pathogens for infants and young children. EPEC belong to a limited number of serotypes (71) , and some EPEC strains have been shown to adhere avidly to the mucosa of the small intestine and produce characteristic effacement of microvilli (1, 16, 77, 99) . Enterohemorrhagic E. coli (EHEC) cause hemorrhagic colitis and are of the serotype 0157:H7 (98). EPEC and EHEC are not enteroinvasive and do not produce the classical heat-stable and heat-labile enterotoxins (71, 98, 117) . We and others (12, 52, 73) have proposed that some EPEC and all EHEC strains may cause intestinal disease by producing elevated levels of Shiga-like cytotoxins. In this section, the discovery and nomenclature of E. coli Shiga-like toxins, as well as the relationship of the toxins to Vero toxins, will be discussed.
Discovery that EPEC and EHEC make Shiga-like toxins.
The initial search for a Shiga-like toxin of E. coli focused on EPEC that caused diarrhea in infant rabbits (13) Letter, 1985) . We have designated (110) the anti-Shiga toxin neutralizable cytotoxin as Shiga-like toxin I (SLT-I), and we have named the other cytotoxin Shiga-like toxin II (SLT-II).
It is important to note that SLT-I predominates in cell lysates and SLT-II is the more active toxin in culture filtrate (110) (67) . Of these 10 strains, 7 were associated with diarrhea in human infants, 1 was associated with diarrhea in a weanling pig, and 2 were isolated from cheese. None of the E. coli strains that made Vero toxin also made E. coli heat-labile or heat-stable enterotoxin. Vero toxin from 8 of the 10 strains was neutralized by antiserum against the Vero toxin from E. coli H30; Vero toxins from an EPEC 0128:B12 and from the pig isolate 0138:K81 were not neutralized by the antiserum. This was the earliest indication that E. coli strains produce more than one toxin active against Vero cells.
The first studies on E. coli isolated from animals Vero toxin concentrated on EPEC and EPEC-like strains (see above) ( 573, 1983 ) by the same series of steps used to purify toxin from S. dysenteriae 1: i.e., French pressure cell disruption of bacteria grown in iron-depleted medium, Affi-Gel Blue chromatography, chromatofocusing, and anti-Shiga toxin affinity chromatography. The SLT-I from EHEC has also been purified by a method that includes ammonium sulfate fractionation, DEAE-cellulose column chromatography, and high-pressure liquid chromatography (M. Noda, N. Nakabayaski, T. Yutsudo, T. Hirayama, and Y. Takeda, Abstr. Toxicon 23:600, 1985) . Each SLT-I purified from these EPEC and EHEC strains was comprised of an A subunit and multiple copies of a B subunit.
The relative mobilities on sodium dodecyl sulfatepolyacrylamide gel electrophoresis of the A and B subunits of the SLT-Is purified from EPEC strain H30 and EHEC strain 933 were indistinguishable from those of the purified Shiga toxin of S. dysenteriae 1 strain 60R when all three samples were run in parallel (O'Brien, et al., Letter, Lancet ii:573, 1983). This observation, together with the data now available on the subunit structure of Shiga toxin (see above) and the translated nucleotide sequence of SLT-I from EHEC strain 933 (see Genetics and Regulation), indicate that the SLT-I A subunit has a MW of 32,200 and the SLT-I B subunit has a MW of 7,700. The value for the A subunit MW is close to that of the original estimate obtained with purified toxin of EPEC strain H30 (31,500 [80] ), but the value for the B subunit is almost twice that estimated from cross-linking studies (80) . By analogy with Shiga toxin, the most likely A-to-B subunit ratio for SLT-I is 1:5. If that is indeed the case, then the MW of holotoxin is ca. 70,000. Previous estimates of the MW of SLT-I have ranged from a low of 10,000 to 30,000 (67; W. G. Wade, B. T. Thom, and N. Evans, Letter, Lancet ii:1235-1236, 1979) to a high of 48,000 (80) . The reason for this range in the reported MW of SLT-I is not known.
SLT-II may have been purified to homogeneity by Padhye et al., who recently reported (90) that they had purified a Vero cell cytotoxin from culture filtrates of E. coli 0157:H7 strain 932 by concentration of filtrates followed by molecular sieve and anion-exchange chromatography. Since the Vero cell cytotoxin prepared by Padhye et al. (90) was not neutralized by anti-Shiga toxin, and since strain 932 produces both SLT-I and SLT-II (73), it seems reasonable to presume that the material isolated by Padhye et al. is SLT-II. Neutralization studies with anti-SLT-II must be done to prove or disprove that hypothesis. One of the problems with isolating one type of SLT from E. coli strains that make both SLT-I and SLT-II is that a toxin preparation could be contaminated with the variant toxin. Indeed, with the discovery by Scotland et al. (Letter, 1985) that E. coli 933 makes not only VT1 (SLT-I) but also VT2 (SLT-II), we reexamined our SLT-I preparation from E. coli 933 for SLT-II. We found no evidence that our preparation of SLT-I was contaminated with SLT-II.
Mode of Action Purified SLT-Is from E. coli H30 (80) and E. coli 933 (O'Brien et al., Letter, Lancet ii:573, 1983) have the same biological activities as and comparable specific activities to purified Shiga toxin: cytotoxicity for HeLa and Vero cells, enterotoxicity for ligated rabbit ileal segments, and lethality at doses between 100 ng and 2 ,ug for mice. By analogy with Shiga toxin, the molecular basis for these three seemingly diverse biological activities is catalytic inactivation of 60S ribosomes in toxin-sensitive (receptor-expressing) cells. To our knowledge, the experiments to test the validity of this analogy have not been done, although crude preparations of E. coli SLT-I do inhibit protein synthesis in HeLa cells (81) . The receptor for SLT-I has been identified (C. A. Lingwood, H. Law, S. Richardson, M. Petric, J. L. Brunton, and M. Karmali, J. Biol. Chem., in press) and is the same as for Shiga toxin. Cell lysates of the lysogenic strain E. coli C600 (933W) were recently used to assess the biological properties of SLT-II (110) . The results of that study indicate that SLT-II has the same three biological properties as SLT-I, but, per unit of protein in cell lysates, it is more lethal for mice and less cytotoxic than SLT-I (110). The phages that determine the production of Shiga-like toxins in E. coli are of several different types that were initially distinguished on the basis of differences in properties such as host range, immunity specificity, and susceptibility to thermal inactivation (84, 108) . E. coli H19 (026) and 933 (0157) are both lysogenic for two different toxinconverting phages. The phages, originally designated H19A (108) and H19J (108) are independent isolates of the same phage from strain H19 that are closely related to phage 933J from strain 933 (108) in terms of their morphology, virion polypeptides, DNA restriction fragments, and immunity specificity, but phage H19B has a different immunity specificity. Phages H19A/J, 933J, and H19B are all lambdoid phages that code for SLT-I. A 8.1-kilobase (kb) EcoRI fragment of the H19B genome was shown to be homologous with the region of the gene of phage lambda that encodes the genes cI, ninR, 0, P, and the origin of replication (44) The organization and expression of the operon for SLT-I are shown schematically in Fig. 2 . The structural genes that encode SLT-I were cloned on a 2.5-kb DNA fragment from a phage from strain H19 (not characterized as H19A or H19B) (119), on a 3.1-kb DNA fragment from phage 933J (78) , and on a 1.7-kb DNA fragment from phage H19B (44 (47a) . The genetic map shows the location for the promotor (P) for the SLT-I operon and the structural genes slt-I A and slt-I B. The mRNA is presumed to be polycistronic. The primary translation products correspond to the unprocessed A and B polypeptides of SLT-I which have amino-terminal signal sequences represented by the wavy lines. The oligomeric holotoxin is presumed to be assembled from the A and B polypeptides after they are secreted and processed to remove the signal sequences.
but not identical. Analysis of appropriate DNA clones and subclones from phage 933J in minicells (78) and from phage H19B in an in vitro protein synthesis system (44) provided direct evidence that the phage genomes code for SLT-I, permitted assignment of the locations of the contiguous sequences coding for polypeptides A and B, and provided evidence for the orientation of transcription. Expression of the B gene by clones from which the promoter and the proximal part of the A gene was deleted indicated that the B gene can also be transcribed from a second promoter. This organization of the toxin operon was confirmed and extended by analysis of transposon insertions and mini-mu lac operon fusions within the genes for SLT-I (119; R. J. Neill (47a) , and preliminary results from the sequencing of the A and B subunit genes from phage H19B have been reported by others (5) . Analysis of the translated amino acid sequences indicates that the A and B polypeptides of SLT-I contain hydrophobic signal sequences at their amino termini and are probably synthesized as precursor forms of secreted periplasmic proteins. The deduced sequence for the mature form of the B polypeptide of SLT-I was identical with the 69-amino-aid sequence determined recently for the B polypeptide of Shiga toxin from S. dysenteriae (106) . These studies therefore establish conclusively that SLT-I from E. coli and Shiga toxin from S. dysenteriae 1 are very closely related, and possibly identical, proteins.
The genetic determinants for a second Vero cytotoxin (VT2) were cloned on a 4.7-kb EcoRI fragment from a phage from E. coli E32511 into the plasmid vector pACYC184 (119) . A 2-kb DNA probe prepared from the 4.7-kb insert of this hybrid plasmid was shown to hybridize with toxinogenic strains of E. coli 0157 that failed to react with another 0.75-kb DNA probe for the SLT-I structural genes, providing direct evidence for two genetically distinct cytotoxins of E. coli. On the basis of evidence that E. coli E32511 produces SLT-II but not SLT-I (110; Scotland et al., Letter, 1985) and that E. coli K-12 lysogenized with the phage from strain E32511 also produces SLT-II only (Scotland et al., Letter, 1985) , it seems almost certain that th, second toxin identified by genetic criteria is the same as the second toxin identified by immunologic criteria. Under conditions of low stringency, the 2-kb DNA probe for SLT-II cloned from the E32511 phage hybridized weakly with the 0.75-kb DNA probe for SLT-I (119), and the 3.1-kb DNA fragment encoding SLT-I from phage 933J described above hybridized with specific restriction fragments of DNA from the SLT-IIconverting phage 933W (110 Little is known about the regulation of production of SLT-I or SLT-II in E. coli. For strains of E. coli that produce both SLT-I and SLT-II, SLT-I is often the predominant toxin present in cell lysates, whereas SLT-II may be present in much higher titer than SLT-I in culture supernatants (16) . This observation suggests that there may be significant differences in secretion or localization of SLT-I and SLT-II in E. coli. Wild-type strains of E. coli have been classified as high-, moderate-, or low-toxin-producing strains on the basis of quantitative titrations of toxin produced by strains grown under rigidly controlled conditions in deferrated medium (73) . All strains of E. coli 0157:H7 associated with hemorrhagic colitis have been characterized as highly toxinogenic, and a significant proportion of EPEC isolates are highly toxinogenic. Most highly toxinogenic strains produce SLT-I, and some also produce SLT-II. Production of SLT-II only is common among strains classified as moderately toxinogenic (73, 110) . All strains of E. coli K-12 examined to date produce low levels of Shiga-like toxin that can be neutralized by polyclonal anti-Shiga toxin or monoclonal antibodies against SLT-I, but the DNA probe for SLT-I from phage 933J described above does not hybridize to any significant extent with DNA from E. coli K-12 strains. The reasons for this apparent discrepancy between the results of immunologic and genetic tests for the SLT of E. coli K-12 strains have not been resolved.
Role in Disease Epidemiological evidence. As is the case with Shiga toxin, there is no direct proof that E. coli SLT-I or SLT-II plays a role in disease. Some of the strongest circumstantial evidence comes from epidemiological studies ofE. coli strains isolated from humans (17, 48a, 52, 73, 105, 108) and animals (15, 53, 54, 73, 76, 107 substrains, EIEC, ETEC,E. coli strains of classical EPEC serogroups isolated from patients with diarrhea, other strains isolated from patients with diarrhea, and three strains (not of the 0157:H7 serotype) isolated from patients with hemorrhagic colitis. Ten strains produced moderate levels of cell-associated cytotoxin, and cytotoxicity could also be detected in culture supernatants. All 10 strains were associated with diarrhea, hemorrhagic colitis, or HUS, and the 10 strains made only SLT-II (110) . A total of 39 strains made high levels of cytotoxin, and 38 of the 39 were associated with diarrhea, hemorrhagic colitis, or HUS. All 39 strains made SLT-I, and 17 of the 39 strains also made SLT-II (110) .
The finding that moderate or high levels of cytotoxin were almost exclusively (48 of 49) found in strains isolated from people with diarrhea, hemorrhagic colitis, or HUS suggests that such elevated levels of cytotoxin may play a role in the pathogenesis of these diseases. However, the mechanism by which elevated levels of SLT-I or SLT-II or both might mediate these diseases has not been determined. It is also not clear whether one of the two Shiga-like toxins is more important than the other in the pathogenesis of each type of enteric disease. It should be emphasized that low levels of cytotoxin might also damage host cells if toxin were produced by an E. coli strain that could adhere avidly to or invade intestinal epithelial cells.
With the realization that moderate-and high-level Shigalike toxin-producing strains are strongly associated with enteric disease and HUS (48a, 52, 73) comes the need for an efficient and sensitive means of detecting such strains in stools. Karmali et al. (51) have described a method for detecting low numbers of Vero toxin-producing E. coli in mixed cultures by a combination of colony "sweeps" (loopfuls of confluent bacterial growth) and polymyxin extraction of cell pellets. The advantages of this procedure are its sensitivity and its capacity to detect both SLT-I and SLT-II-producing strains of E. coli. The major disadvantage of the procedure is the need to have tissue culture facilities available in the clinical laboratory. This is a particular problem for small laboratories and for nearly all laboratories in developing countries. A colony enzyme-linked immunosorbent assay that permits direct detection of high-level SLT-I-producing E. coli on agar plates was recently described (109) . In that assay, cultures are grown on iron-depleted agar supplemented with subinhibitory doses of trimethoprimsulfamethoxazole, an antimicrobial mixture that stimulates Shiga and Shiga-like toxin synthesis (50) . This observation was made when Karch et al. (48) tested several antimicrobial agents for their effects on toxin production. After samples are inoculated onto the agar containing trimethoprimsulfamethoxazole, plates are incubated overnight, and bacterial colonies are then transferred to nitrocellulose by blotting. Toxin is released from the colonies on the nitrocellulose with polymyxin B, and the toxin bound to the membrane is detected by addition of monoclonal antibody to the B subunit of SLT-I, a horseradish peroxidase-coupled second antibody, and substrate. The advantages of the colony enzyme-linked immunosorbent assay are its direct application to stool cultures and its sensitivity and specificity (109) . The disadvantage of the assay is that it will detect only E.
coli that produce high levels of SLT-I (109) . A monoclonal antibody specific for SLT-II will have to be developed and incorporated into the assay to detect E. coli that make only SLT-II.
Animal models. Several animal models have been developed for studying the (92) . The infant rabbit, the gnotobiotic pig, and the gnotobiotic calf (D. Francis, personal communication) seem to be appropriate models for studying colonization and induction of diarrhea after oral infection with E. coli 0157:H7 strains. The mechanism of colonization of the gnotobiotic pig by E. coli 0157:H7 resembles the attach-andefface mode of classical EPEC (reviewed in reference 71), except that colonization by EHEC of the gnotobiotic pig is apparently not plasmid mediated (S. Tzipori and R. RobinsBrowne, personal communication). However, a large plasmid of 60 to 70 megadaltons is present in most isolates ofE. coli 0157:H7 (117; Johnson et al., Letter, 1983) , and that plasmid is associated with the expression of a unique fimbrial antigen (49) .
In a very interesting study by Pai et al. (92) , it was observed that 3-day-old rabbits inoculated intragastrically with 108 E. coli 0157:H7 cells consistently developed diarrhea. The damage to the mucosal epithelium was seen mainly in the mid-and distal colon and was characterized by apoptosis (defined by Pai et al. [92] as "individual cell death") in the surface epithelium, increased mitotic activity in the crypts, mucin depletion, and a mild to moderate infiltration of neutrophils in the lamina propria and epithelium. Pai et al. (92) also found that infant rabbits developed diarrhea when given partially purified Vero toxin (isolated from culture filtrates of E. coli 0157:H7 and therefore probably predominately SLT-II). Furthermore, these investigators noted that the mucosal abnormalities of rabbits inoculated with toxin alone mimicked those seen when the intact organism was used. It is of note that apoptosis was a striking feature of the histopathological damage to adult rabbit ileum after exposure to purified Shiga toxin or SLT-I (55).
SHIGA-LIKE TOXINS IN OTHER BACTERIA
Some strains of Vibrio cholerae and Vibrio parahaemolyticus make low levels of a cell-associated cytotoxin for HeLa cells that can be neutralized by polyclonal anti-Shiga toxin (A. D. O'Brien, M. E. Chen, R. K. Holmes, J. Kaper, and M. M. Levine, Letter, Lancet, i: [77] [78] 1984) and monoclonal antibody to the B subunit of SLT-I (109) . We have previously speculated (O'Brien et al., Letter, 1984 ) that a Shiga-like toxin might be responsible for the diarrhea occasionally seen with volunteers fed V. cholerae strains that do not make cholera enterotoxin, such as JBK70 (47) . One of the ways to test this hypothesis is to construct V. cholerae strains that no longer contain the Shiga-like toxin genes and to compare the diarrhea-evoking potential of the mutant with that of its parent. Experiments to produce such mutants are in progress (J. Kaper, personal communication) . In addition to the Vibrio sp., a strain of Salmonella typhimurium (82, 109) and several isolates of Campylobacter jejuni (M. M. Moore, M. J. Blaser, G. I. Perez-Perez, and A. D. O'Brien) have been found to produce low levels of a cytotoxin neutralized by anti-Shiga toxin. The role, if any, that these toxins play in the pathogenesis of salmonellosis and campylobacteriosis remains to be determined. Moreover, the frequency of Shiga-like toxin synthesis by S. typhimurium and C. jejuni is unknown. To date, no bacteria other than E. coli have been shown to produce a cytotoxin neutralized by reference anti-SLT-II sera.
CONCLUSION
The main purpose of this review was to summarize the results of recent studies leading to the purification and characterization of S. dysenteriae 1 toxin and the immunologically related E. coli Shiga-like toxin, as well as the cloning and characterization of the structural genes for E. coli SLT-I. Determination of the nucleotide sequences of the structural genes and the corresponding amino acid sequences for the structural polypeptides for all known members of the Shiga toxin family in the near future is technically feasible. Such studies will provide unequivocal evidence about the extent of genetic and structural homology among these toxins, but additional studies are required for detailed knowledge concerning the three-dimensional structures of the toxins and the relationships between structure, receptorbinding activity, mechanism(s) for inactivation of protein synthesis, and biologically important antigenic determinants. The availability of the cloned toxin genes, highly specific monoclonal antitoxic antibodies, and purified toxins provides a powerful set of tools for molecular analysis of these and other aspects of Shiga and Shiga-like toxins.
At present, the role of Shiga toxin in the pathogenesis of infectious diseases caused by Shigella spp. remains highly suggestive but inconclusive. No strains of S. dysenteriae 1 have been identified that are virulent but fail to produce Shiga toxin. It should be feasible to produce genetically engineered, isogenic strains of S. dysenteriae 1 that differ only with respect to their toxinogenicity or nontoxinogenicity and to perform direct tests to determine whether the toxin is an essential or an accessory virulence factor for the pathogenesis of shigellosis. Analogous studies should also be done with other Shigella species. All efforts to date to prevent shigellosis by antitoxic immunity have been unsuccessful, but reliable methods for inducing secretory antitoxic antibodies in the gut are not yet available.
Epidemiological studies have established that production of high or moderate levels of Shiga-like toxins is associated with many EPEC and most EHEC strains that cause disease in humans. Furthermore, E. coli or Shigella strains that produce high or moderate levels of toxin are frequently isolated from patients with HUS. Most strains of E. coli that cause edema disease in pigs also produce elevated levels of Shiga-like toxin. Many of these studies do not differentiate between the antigenic variants of Shiga-like toxins; therefore, additional studies are needed to define more precisely the prevalence of SLT-I and SLT-II among such strains and to establish whether other serotypes or serovariants exist among the Shiga-like toxins of E. coli.
The observation that active immunization against Shiga toxin does not provide protection against shigellosis in experimental animals (74) does not provide definitive evidence against a pathogenic role for Shiga or Shiga-like toxins. The pathogenesis of such infections involves several different kinds of interaction between bacteria and host cells. Shigella spp. are able to invade and multiple within colonic epithelial cells, and EPEC become closely associated and efface the microvilli of enterocytes. Toxin could be produced in the intracellular environmnt or delivered to target cells by direct contact with bacterial cells, and such toxin might not be accessible to neutralization by antibodies in the extracellular milieu. The nature of the interaction between EHEC and target cells in the intestines of infected humans is not yet clearly defined. For HUS and edema disease, it has been postulated that toxin may be disseminated hematogenously from the intestinal tract and reach putative target cells such as the vascular endothelium in distant organs. If toxin released from bacterial cell has an essential or adjunctive role in pathogenesis, then specific antitoxic immunity might be effective for prevention or treatment of some of these diseases. 
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